Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc. reported a total net revenue increase of 3.7% year-over-year, reaching $69.4 million, largely attributed to higher volumes of Jeuveau and the successful launch of the Evolysse dermal filler line. The company's optimism is bolstered by a projected contribution from Evolysse to top-line guidance expected to reach approximately $33 million in 2025, reflecting strong initial market demand. Furthermore, there is a growing trend among younger consumers favoring aesthetic treatments, which is anticipated to drive significant market growth and enhance Jeuveau's market share as demand recovers.

Evolus's adjusted gross margin decreased to 66.5% from 71.5% over the past year, largely attributed to a higher mix of international sales and introductory pricing strategies. The company substantially revised its 2025 net revenue guidance downward to $295-$305 million, reflecting a growth expectation of only 11%-15%, in stark contrast to the previously anticipated 30%-33%. Furthermore, Jeuveau's sales in Q2 2025 dropped to $59 million, marking the first year-over-year decline since its launch, which suggests diminishing consumer sentiment and a broader downturn in the U.S. aesthetic market.